|
1
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pattabiraman DR and Weinberg RA: Tackling
the cancer stem cells - what challenges do they pose? Nat Rev Drug
Discov. 13:497–512. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koren E and Fuchs Y: The bad seed: Cancer
stem cells in tumor development and resistance. Drug Resist Updat.
28:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sánchez-Tilló E, Lázaro A, Torrent R,
Cuatrecasas M, Vaquero EC, Castells A, Engel P and Postigo A: ZEB1
represses E-cadherin and induces an EMT by recruiting the SWI/SNF
chromatin-remodeling protein BRG1. Oncogene. 29:3490–3500. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chaffer CL, Marjanovic ND, Lee T, Bell G,
Kleer CG, Reinhardt F, D'Alessio AC, Young RA and Weinberg RA:
Poised chromatin at the ZEB1 promoter enables breast cancer cell
plasticity and enhances tumorigenicity. Cell. 154:61–74. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y,
Zhang J, Yuan J, Wang M, Chen D, Sun Y, et al: ATM-mediated
stabilization of ZEB1 promotes DNA damage response and
radioresistance through CHK1. Nat Cell Biol. 16:864–875. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cortez MA, Valdecanas D, Zhang X, Zhan Y,
Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, et al:
Therapeutic delivery of miR-200c enhances radiosensitivity in lung
cancer. Mol Ther. 22:1494–1503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang P, Wang L, Rodriguez-Aguayo C, Yuan
Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, et al: miR-205
acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat
Commun. 5:56712014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Srivastava M and Raghavan SC: DNA
double-strand break repair inhibitors as cancer therapeutics. Chem
Biol. 22:17–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tian H, Gao Z, Li H, Zhang B, Wang G,
Zhang Q, Pei D and Zheng J: DNA damage response - a double-edged
sword in cancer prevention and cancer therapy. Cancer Lett.
358:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Skvortsov S, Debbage P, Lukas P and
Skvortsova I: Crosstalk between DNA repair and cancer stem cell
(CSC) associated intracellular pathways. Semin Cancer Biol.
31:36–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fokas E, Prevo R, Hammond EM, Brunner TB,
McKenna WG and Muschel RJ: Targeting ATR in DNA damage response and
cancer therapeutics. Cancer Treat Rev. 40:109–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benada J and Macurek L: Targeting the
checkpoint to kill cancer cells. Biomolecules. 5:1912–1937. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weigelt K, Moehle C, Stempfl T, Weber B
and Langmann T: An integrated workflow for analysis of ChIP-chip
data. Biotechniques. 45:131–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ji X, Li W, Song J, Wei L and Liu XS:
CEAS: Cis-regulatory element annotation system. Nucleic Acids Res.
34:(Web Server issue). W551–W554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sekido R, Murai K, Funahashi J, Kamachi Y,
Fujisawa-Sehara A, Nabeshima Y and Kondoh H: The delta-crystallin
enhancer-binding protein delta EF1 is a repressor of
E2-box-mediated gene activation. Mol Cell Biol. 14:5692–5700. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Remacle JE, Kraft H, Lerchner W, Wuytens
G, Collart C, Verschueren K, Smith JC and Huylebroeck D: New mode
of DNA binding of multi-zinc finger transcription factors: deltaEF1
family members bind with two hands to two target sites. EMBO J.
18:5073–5084. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Delgado-Díaz MR, Martín Y, Berg A, Freire
R and Smits VA: Dub3 controls DNA damage signalling by direct
deubiquitination of H2AX. Mol Oncol. 8:884–893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ahel D, Horejsí Z, Wiechens N, Polo SE,
Garcia-Wilson E, Ahel I, Flynn H, Skehel M, West SC, Jackson SP, et
al: Poly(ADP-ribose)-dependent regulation of DNA repair by the
chromatin remodeling enzyme ALC1. Science. 325:1240–1243. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Furgason JM and Bahassi M: Targeting DNA
repair mechanisms in cancer. Pharmacol Ther. 137:298–308. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burrows JF, McGrattan MJ, Rascle A,
Humbert M, Baek KH and Johnston JA: DUB-3, a cytokine-inducible
deubiquitinating enzyme that blocks proliferation. J Biol Chem.
279:13993–14000. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu H, Wang Z, Jin S, Hao H, Zheng L, Zhou
B, Zhang W, Lv H and Yuan Y: Dux4 induces cell cycle arrest at G1
phase through upregulation of p21 expression. Biochem Biophys Res
Commun. 446:235–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Karimian A, Ahmadi Y and Yousefi B:
Multiple functions of p21 in cell cycle, apoptosis and
transcriptional regulation after DNA damage. DNA Repair (Amst).
42:63–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ciccia A and Elledge SJ: The DNA damage
response: Making it safe to play with knives. Mol Cell. 40:179–204.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weber AM and Ryan AJ: ATM and ATR as
therapeutic targets in cancer. Pharmacol Ther. 149:124–138. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aparicio T, Baer R and Gautier J: DNA
double-strand break repair pathway choice and cancer. DNA Repair
(Amst). 19:169–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng W, Su Y and Xu F: CHD1L: A novel
oncogene. Mol Cancer. 12:1702013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jung YS, Qian Y and Chen X: Examination of
the expanding pathways for the regulation of p21 expression and
activity. Cell Signal. 22:1003–1012. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rohleder F, Huang J, Xue Y, Kuper J, Round
A, Seidman M, Wang W and Kisker C: FANCM interacts with PCNA to
promote replication traverse of DNA interstrand crosslinks. Nucleic
Acids Res. 44:3219–3232. 2016. View Article : Google Scholar : PubMed/NCBI
|
